SCHEMBL310346

SCHEMBL310346

Cc1cc(C=O)c(C)c([SiH3])c1C

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
TSHR P16473 2/20 0.38
ERN1 O75460 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
GRIA1 P42261 1/20 0.35
GRIA2 P42262 1/20 0.35
GRIA3 P42263 1/20 0.35
GRIA4 P48058 1/20 0.35
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
MPI P34949 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28763301 0.82 ALDH1A1 (0.38) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL1313141 0.78 ALDH1A1 (0.42) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL7946621 0.77
SCHEMBL7700297 0.74 ALDH1A1 (0.39) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL547850 0.74 ALDH1A1 (0.39) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL27601277 0.74 CYP3A4 (0.33) TSHRCYP3A4
SCHEMBL2474437 0.73 CYP1A2 (0.44) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL8761629 0.73 ERN1 (0.52) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL446933 0.72 ALDH1A1 (0.50) ALDH1A1TSHRERN1SMN1; SMN2GRIA1
SCHEMBL2884919 0.72 GRIA1 (0.56) ALDH1A1TSHRERN1SMN1; SMN2GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093406-B2 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2012-01-10 US disclosed
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors BACE2, BACE1, APP ALDH1A1 2566/4885TSHR 4855/4885ERN1 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.